American drug activist

Richard Elliot Doblin (born November 30, 1953) is an American drug activist and executive who is the founder and executive director of the Multidisciplinary *ociation for Psychedelic Studies (MAPS).

Contents

• 1 Life and career
• 2 Bibliography
• 3 See also
• 4 References
• 5 External links

Life and career

Born in 1953, Doblin grew up in a Conservative Jewish family in suburban Chicago. He is the first of four children to pediatrician Morton Doblin and schoolteacher Arline Doblin. He has three younger siblings, Bruce, Sharon, and Stuart Doblin.

From 1975 until 1982, Doblin owned and operated a company called Braxas Construction, located in the Sarasota, Florida area, which specialized in relocating houses. In 2001 he received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and * and his Master's thesis on a survey of oncologists about smoked * vs. the oral THC pill in nausea control for cancer patients.

Doblin obtained a psychology degree from New College of Florida in 1987. His undergraduate thesis at New College of Florida was a 25-year follow-up to the cl*ic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork prac*ioner.

He co-founded Earth Metabolic Design Laboratories in 1984 to support psychedelic research and Multidisciplinary *ociation for Psychedelic Studies (MAPS) in 1986 with the goal of making MDMA an FDA-approved medicine.

Rick Doblin's life is profiled in former Washington Post Magazine editor Tom Shroder's book Acid Test: LSD, Ecstasy, and the Power to Heal.

Doblin married Lynne Doblin in 1993. Together they have three children Eden, Lilah, and Eliora and live in Boston, M*achusetts.

Bibliography

• Frith, C.; Chang, L.; Lattin, D.; Walls, R.; Hamm, J.; Doblin, R. (1987). "Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat". Fundamental and Applied Toxicology. 9 (1): 110–19. doi:10.1016/0272-0590(87)90158-8. PMID:2887476.
• Doblin, R. (1991). "Pahnke's "Good Friday Experiment": A long-term follow-up and methodological critique" (PDF). Journal of Transpersonal Psychology. 23 (1): 1–28. Archived from the original (PDF) on 2014-01-16.
• Doblin, R.; Kleiman, M. (May 1, 1991). "Medical use of *". Annals of Internal Medicine. 114 (9): 809–10. doi:10.7326/0003-4819-114-9-809_3. PMID:1842667.
• Doblin, R.; Kleiman, M. (July 1991). "* as antiemetic medicine: a survey of oncologists' experiences and at*udes". Journal of Clinical Oncology. 9 (7): 1314–1319. doi:10.1200/JCO.1991.9.7.1314. PMID:2045870.
• Grinspoon, L.; Bakalar, J.; Doblin, R. (1995). "*, the AIDS wasting syndrome, and the U.S. government". The New England Journal of Medicine. 333 (10): 670–1. doi:10.1056/nejm199509073331020. PMID:7637743.
• Doblin, R.; Kleiman, M. (1995). "The medical use of *: the case for clinical trials". Journal of Addictive Diseases. 14 (1): 5–14. doi:10.1300/J069v14n01_02. PMID:7543287.
• Doblin, R.; Kleiman, M. (1998). "Survey research vs clinical trials in evaluating the medical utility of *". Southern Medical Journal. 91 (10): 989–91. doi:10.1097/00007611-199810000-00032. PMID:9786301.
• Doblin, R. (1998). "Dr. Leary's Concord Prison Experiment" (PDF). Journal of Psychoactive Drugs. 30 (4): 419–426. doi:10.1080/02791072.1998.10399715. PMID:9924845. Archived from the original (PDF) on 2012-10-30.
• Regulation of the Medical Use of Psychedelics and * . A dissertation by R. Doblin for his Ph.D. in Public Policy from the Kennedy School of Government, Harvard University. June 2002.
• Doblin, R. (Autumn 2002). "A Clinical Plan for MDMA (Ecstasy) in the Treatment of Post-traumatic Stress Disorder (PTSD): Partnering with the FDA" (PDF). MAPS Bulletin. 12 (3): 5–18.
• Mithoefer, M.; Jerome, L.; Doblin, R. (2003). "MDMA ('ecstasy') and neurotoxicity". Science. 300 (5625): 1504–5. doi:10.1126/science.300.5625.1504. PMID:12791964. S2CID:38721229.
• Summall, H.; Jerome, L.; Doblin, R. (2004). "Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psyc*tor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450". Psychopharmacology. 171 (2): 229–30. doi:10.1007/s00213-003-1599-3. PMID:14634709. S2CID:10861824.
• Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Doblin, R. (2010). "The safety and efficacy of 3,4-methylenedioxymethamphetamine *isted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study" (PDF). Journal of Psychopharmacology. 25 (4): 439–452. doi:10.1177/0269881110378371. PMC:3122379. PMID:20643699.
• Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Martin, S.; Yazar-Klosinski, B.; Michel, Y.; Brewerton, T.; Doblin, R. (2012). "Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-*isted psychotherapy: a prospective long-term follow-up study" (PDF). Journal of Psychopharmacology. 27 (1): 28–39. doi:10.1177/0269881112456611. PMC:3573678. PMID:23172889. Archived from the original (PDF) on 2014-06-17.
• G*er, P.; Holstein, D.; Michel, Y.; Doblin, R.; Yazar-Klosinski, B.; P*ie, T.; Brenneisen, R. (2014). "Safety and Efficacy of Lysergic Acid Diethylamide-*isted Psychotherapy for Anxiety *ociated With Life-threatening Diseases" (PDF). The Journal of Nervous and Mental Disease. 202 (7): 513–20. doi:10.1097/NMD.0000000000000113. PMC:4086777. PMID:24594678. Archived from the original (PDF) on 2014-06-24.

See also

• Psychedelia:– Film about the history of psychedelic drugs

References

• The MAPS Staff
• Erowid character vaults
• Miliard, Mike: This is your brain on drugs: Rick Doblin thinks pot, ecstasy, and other psychedelics could unlock the human mind — and he wants to bring them to Harvard, the FDA, and a doctor’s office near you, The Boston Phoenix, Oct. 8-14, 2004.
• Bleyer, Jennifer (October 8, 2013). "Can Ecstasy, Primarily Known as a Club Drug, Help People Suffering From Trauma?". Tablet.
• Cox, Billy (14 August 2008). "Had a nice trip. Wish you could, too". Herald Tribune. Retrieved 2 November 2012.

External links

• Rick Doblin discusses the current state of research on MDMA (aka 'Ecstasy') and the possible benefits
• An interview with Rick Doblin features information about his background and career